Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
1.740
+0.020 (1.16%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Inovio Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 65.81 | 14.31 | 46.33 | 71.14 | 250.73 | Upgrade
|
| Short-Term Investments | 28.3 | 130.98 | 206.67 | 330.17 | 160.91 | Upgrade
|
| Cash & Short-Term Investments | 94.11 | 145.29 | 253 | 401.31 | 411.64 | Upgrade
|
| Cash Growth | -35.23% | -42.57% | -36.96% | -2.51% | 359.76% | Upgrade
|
| Receivables | 1.2 | 2.41 | 11.74 | 8.03 | 19.06 | Upgrade
|
| Prepaid Expenses | 2.52 | 5.41 | 20.51 | 39.1 | 4.8 | Upgrade
|
| Other Current Assets | - | - | 30 | - | 35.66 | Upgrade
|
| Total Current Assets | 97.83 | 153.11 | 315.24 | 448.44 | 471.17 | Upgrade
|
| Property, Plant & Equipment | 11.77 | 14.45 | 17.96 | 29.02 | 24.09 | Upgrade
|
| Long-Term Investments | 1.61 | 2.78 | 2.01 | 3.91 | 4.89 | Upgrade
|
| Goodwill | - | - | 10.51 | 10.51 | 10.51 | Upgrade
|
| Other Intangible Assets | - | - | 2.13 | 2.63 | 3.15 | Upgrade
|
| Other Long-Term Assets | 1.98 | 0.61 | 0.68 | 1.43 | 25.96 | Upgrade
|
| Total Assets | 113.2 | 170.95 | 348.53 | 495.94 | 539.77 | Upgrade
|
| Accounts Payable | 6.44 | 4.65 | 21.08 | 27.97 | 1.47 | Upgrade
|
| Accrued Expenses | 13.13 | 18.64 | 26.42 | 30.55 | 30.08 | Upgrade
|
| Current Portion of Long-Term Debt | - | 16.77 | - | - | - | Upgrade
|
| Current Portion of Leases | 2.5 | 2.41 | 2.8 | 2.6 | 2.33 | Upgrade
|
| Current Unearned Revenue | - | 0.11 | 2.56 | 4.62 | 7.58 | Upgrade
|
| Other Current Liabilities | 13.26 | - | 44 | - | 0.25 | Upgrade
|
| Total Current Liabilities | 35.33 | 42.57 | 96.87 | 65.74 | 41.71 | Upgrade
|
| Long-Term Debt | - | - | 16.61 | 14.96 | 18.66 | Upgrade
|
| Long-Term Leases | 9.37 | 11.03 | 12.66 | 15.46 | 18.06 | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | 0.06 | 0.12 | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | - | 0.03 | 0.03 | 0.03 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | 0.01 | 0.06 | Upgrade
|
| Total Liabilities | 44.69 | 53.6 | 126.17 | 96.27 | 78.63 | Upgrade
|
| Common Stock | 0.04 | 0.02 | 0.02 | 0.22 | 0.19 | Upgrade
|
| Additional Paid-In Capital | 1,799 | 1,741 | 1,711 | 1,610 | 1,367 | Upgrade
|
| Retained Earnings | -1,730 | -1,623 | -1,488 | -1,210 | -906.2 | Upgrade
|
| Comprehensive Income & Other | -0.68 | -0.66 | -0.7 | -0.28 | -0.26 | Upgrade
|
| Total Common Equity | 68.5 | 117.35 | 222.36 | 399.67 | 461.14 | Upgrade
|
| Shareholders' Equity | 68.5 | 117.35 | 222.36 | 399.67 | 461.14 | Upgrade
|
| Total Liabilities & Equity | 113.2 | 170.95 | 348.53 | 495.94 | 539.77 | Upgrade
|
| Total Debt | 11.87 | 30.21 | 32.07 | 33.02 | 39.05 | Upgrade
|
| Net Cash (Debt) | 82.25 | 115.08 | 220.92 | 368.29 | 372.59 | Upgrade
|
| Net Cash Growth | -28.53% | -47.91% | -40.01% | -1.16% | - | Upgrade
|
| Net Cash Per Share | 3.03 | 5.19 | 11.11 | 21.16 | 28.82 | Upgrade
|
| Filing Date Shares Outstanding | 36.67 | 23.37 | 21.68 | 18.12 | 17.3 | Upgrade
|
| Total Common Shares Outstanding | 36.1 | 22.79 | 21.09 | 18.12 | 15.57 | Upgrade
|
| Working Capital | 62.5 | 110.54 | 218.37 | 382.7 | 429.46 | Upgrade
|
| Book Value Per Share | 1.90 | 5.15 | 10.54 | 22.06 | 29.62 | Upgrade
|
| Tangible Book Value | 68.5 | 117.35 | 209.72 | 386.53 | 447.48 | Upgrade
|
| Tangible Book Value Per Share | 1.90 | 5.15 | 9.94 | 21.34 | 28.74 | Upgrade
|
| Machinery | 8.36 | 9.9 | 13.49 | 20.59 | 12.16 | Upgrade
|
| Leasehold Improvements | 11.76 | 15.92 | 15.8 | 15.8 | 15.18 | Upgrade
|
Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.